number of codes in a given transaction may be necessary to report the same information reported with ICD–9 codes because ICD–10 codes are more specific.  
Affected Public: Private Sector (Business or other for-profits, Not-for-profit institutions). Number of Respondents: 696,026. Total Annual Responses: 696,026. Total Annual Hours: 6,960,260.  
(For policy questions regarding this collection contact Gladys Wheeler at 410–786–0273. For all other issues call 410–786–1326.)

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access CMS’ Web site address at http://www.cms.hhs.gov/PaperworkReductionActof1995, or Email your request, including your address, phone number, OMB number, and CMS document identifier, to Paperwork@cms.hhs.gov, or call the Reports Clearance Office on (410) 786–1326.

To be assured consideration, comments and recommendations for the proposed information collections must be received by the OMB desk officer at the address below, no later than 5 p.m. on April 22, 2013.

OMB: Office of Information and Regulatory Affairs, Attention: CMS Desk Officer, Fax Number: (202) 395–6974. Email: OIRA_submission@omb.eop.gov.

Dated: March 18, 2013.

Martique Jones,  
Deputy Director, Regulations Development Group, Office of Strategic Operations and Regulatory Affairs.  
[FR Doc. 2013–06534 Filed 3–20–13; 8:45 am]  
BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[CFDA Number: 93.576]

Announcement of the Award of an Urgent Single-Source Grant to the Center for Survivors of Torture in Dallas, TX

AGENCY: Office of Refugee Resettlement, Administration for Children and Families, Department of Health and Human Services.

ACTION: Announcement of the award of an urgent single-source grant to the Center for Survivors of Torture to provide mental health services for refugees.

SUMMARY: The Administration for Children and Families (ACF), Office of Refugee Resettlement (ORR) announces the award of an urgent single-source grant in the amount of $250,000 to the Center for Survivors of Torture (CST) in Dallas, TX to ensure incoming refugee populations in Texas have access to mental health services.

DATES: The project period for the award is February 1, 2013 through January 31, 2014.

FOR FURTHER INFORMATION CONTACT: Kenneth Tota, Deputy Director, Office of Refugee Resettlement, 901 D Street SW., Washington, DC 20047, Telephone: 202–401–4838. Email: kenneth.tota@acf.hhs.gov.

SUPPLEMENTARY INFORMATION: Approximately 45,000 individual refugees reside in the areas covered by the Center for Survivors of Torture. Texas and the surrounding region have a demonstrated history of being a top resettlement location with one of the highest concentrations of refugees in the United States. In the past few years, the Office of Refugee Resettlement (ORR) has seen an increasing need for mental health services associated with the three primary refugee populations from Iraq, Burma and Bhutan who have suffered extreme trauma and torture due to war and genocide in those countries.

Refugees from Bhutan have specifically demonstrated a high incidence of suicide upon arrival to the U.S. ORR has been working closely with the Centers for Disease Control (CDC) to assess this situation. The CDC recently published a study recommending enhanced mental health services for incoming refugees from Bhutan.

This fiscal year the program is seeing a significant increase in resettlement of refugees from the Democratic Republic of Congo. The United Nations High Commissioner for Refugees (UNHCR) has determined this group is particularly at risk due to decades of extreme violence in the Democratic Republic of Congo and recent arrivals have shown a compelling need for mental health services upon arrival. Furthermore, CST is the only accredited mental health care provider of specialized refugee mental health treatment services in Texas and the surrounding area.

CST services are critical to meeting refugee mental health needs by providing services such as an initial assessment, counseling to: children, adolescents, adults, couples, and families. Additionally, CST provides groups therapy, psychoeducational groups, testing for mental health conditions, and medication management. In addition to these direct services, CST also provides training to other agencies in the area to include schools, health clinics, and social services agencies on refugee mental health issues.

Due to the high number of refugees being resettled in this region, with no other demonstrated provider of expert mental health services to this population, this grant is urgent and critical to those in need of such services. According to the Department of State, Texas is projected to receive the highest number of refugees admitted to the U.S. in FY13. Through this grant ORR will ensure there is no disruption in much needed mental health services to these particularly at risk populations. This urgent grant will support the provision of these much needed mental health services to ensure these refugees are afforded a successful path to self-sufficiency.


Eskinder Negash,  
Director, Office of Refugee Resettlement.  
[FR Doc. 2013–06517 Filed 3–20–13; 8:45 am]  
BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2013–N–0001]

Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public. This meeting is being rescheduled due to the postponement of the March 7, 2013, Pulmonary-Allergy Drugs Advisory Committee meeting due to unanticipated weather conditions.

Name of Committee: Pulmonary-Allergy Drugs Advisory Committee.  
General Function of the Committee: To provide advice and recommendations to the Agency on FDA’s regulatory issues.

Date and Time: The meeting will be held on April 17, 2013, from 8 a.m. to 5 p.m. This meeting is being rescheduled because of a postponed meeting announced in the Federal
FDA intends to make background material available to the public no later than 7 days in advance of the meeting. Persons attending FDA’s advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Cindy Hong at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: March 15, 2013.

Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.

BILLING CODE 4160–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2013–N–0001]

Risk Communications Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Risk Communications Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the Agency on FDA’s regulatory issues.

Date and Time: The meeting will be held on April 29, 2013, from 8 a.m. to 5 p.m. and on April 30, 2013, from 8 a.m. to 3 p.m.

Location: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993. Information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: http://www.fda.gov/AboutFDA/FDAInfo/contact/fdacomm.htm.

Contact Person: Luis G. Bravo, Designated Federal Officer, Risk Communication Staff, Office of Planning, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3274, Silver Spring, MD 20993, 240–402–5274, FAX: 301–847–8609, email: RCAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.

Therefore, you should always check the Agency’s Web site at http://www.fda.gov/AdvisoryCommittees/about.html, and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting.